CUR Stock DD Neuralstem, Inc. 11/04/2014 06:31:18

Message Board

Previous

| Next

Post# of 250685

Posted On: 11/04/2014 7:31:13 AM

Posted By: Rosner

CUR Neuralstem, Inc. $CUR Company Overview

Stock Message Board Recent Posts http://investorshangout.com/search?q=CUR&...mp;yt0=Go!

Last Updated: 11/04/2014 06:31:14

Current Price and Quotes
Last Price 2.79
Previous Close 2.75 Open 2.76
Daily Range 2.73 - 2.82 52wk Range 2.12 - 4.80
Volume 326,036 Dividend N/A
Average Vol (30d) 624,696 Yield N/A

Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 110 408 391 733
Cost of Revenue - - - -
Gross Profit 110 408 391 733
Operating Expenses

Research and Development 7,134 6,106 7,355 9,164
Sales, General and Admin. 5,255 4,247 5,839 6,624
Non-Recurring Items - - - -
Other 245 211 187 131
Operating Income (12,524) (10,156) (12,990) (15,185)
Income From Continuing Operations

Add'l Income/Expense Items (5,914) 38 473 (3,200)
Earnings Before Interest and Tax (18,438) (10,119) (12,518) (18,385)
Interest Expense 1,394 3 1 3
Earnings Before Tax (19,832) (10,122) (12,519) (18,387)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (19,832) (10,122) (12,519) (18,387)
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (19,832) (10,122) (12,519) (18,387)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (19,832) (10,122) (12,519) (18,387)

Recent News
Source
Oct 23, 2014 Neuralstem Alzheimer's Disease Animal Data Presented At The Congress Of Neurological Surgeons Annual Meeting PR NEWSWIRE
Oct 20, 2014 After Hour Gainers / Losers Seeking Alpha
Oct 20, 2014 Midday Gainers / Losers Seeking Alpha
Oct 20, 2014 Cytokinetics ALS drug impacts disease progression in Phase 2b trial Seeking Alpha
Oct 20, 2014 Genervon ALS drug shows encouraging results Seeking Alpha
Oct 16, 2014 InVivo, Neuralstem Treat Spinal Cord Injury Patients Seeking Alpha
Oct 10, 2014 First patient dosed in spinal cord injury stem cell trial Seeking Alpha
Oct 9, 2014 First Patient Treated In Neuralstem Phase I Spinal Cord Injury Stem Cell Trial Through The UC San Diego Sanford Stem Cell Clinical Center PR NEWSWIRE
Sep 22, 2014 Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data PR NEWSWIRE
Sep 5, 2014 Neuralstem President And CEO To Present At The 2014 Rodman & Renshaw Annual Global Investment Conference PR NEWSWIRE

1
2
next >

(0)

(0)